右丙亚胺对乳腺癌患者术后表阿霉素联合化疗时的心脏保护作用

Cardioprotective Effect of Cardioxane in Patients after Breast Cancer Surgery with Epirubicin Combined with Chemotherapy

目的探讨右丙亚胺对乳腺癌患者术后表阿霉素联合化疗时的心脏保护作用。方法选取在我院进行治疗的乳腺癌患者60例,按照随机数字表的方法平均分为观察组和对照组,两组均采用术后表阿霉素联合化疗的治疗方法,观察组在化疗的基础上给予右丙亚胺治疗。两组患者均进行4个疗程的化疗。进行为期1年的随访,比较两组患者的心电图异常率、心肌钙蛋白和左心室射血分数。结果化疗第4周期、治疗后半年、治疗后1年,观察组的心电图异常率均显著低于对照组(P<0.05)。从化疗第1周期开始,观察组的心肌钙蛋白显著低于对照组,左心室射血分数显著高于对照组(P<0.05)。结论表阿霉素在化疗的第1周期就开始产生心脏毒性,而右丙亚胺能够降低这种心脏毒性,有效地保护心脏。

Objective To explore the cardioprotective effect of cardioxane in patients after breast cancer surgery with epirubicin combined with chemotherapy. Methods 60 cases of patients with breast cancer admitted to our hospital were randomly divided into observation group and control group equally. The two groups were treated with epirubicin combined with chemotherapy after surgery, while the observation group was treated with cardioxane on this basis. Patients in two groups were treated with 4 courses of chemotherapy. After one-year followed-up, the electrocardiographic abnormality rate, cardiac troponin and left ventricular ejection fraction were comparedbetween two groups. Results The electrocardiographic abnormality rate of observation group was significantly lower than that of control group in the fourth-cycle of chemotherapy, half a year and one year after the treatment （P 〈0.05）. From the first cycle of chemotherapy, the cardiac troponin of observation group was significantly lower than that of control group, and the left ventricular ejection fraction was significantly higher than that of control group （both P〈0.05）. Conclusions Epirubicin starts to induce cardiotoxicity in the first cycle of chemotherapy, but cardioxane can reduce the cardiotoxicity and effectively protect the heart.